Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II

Barnes, David W.; Loutit, J. F.

doi:10.1111/j.1365-2141.1957.tb05793.x

Cited by 222 publications

(57 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results contribute to the recent concept of autologous graft vs tumor (GVT) effect, which is based on the fact that immune recovery after ASCT in several malignancies (hematological and nonhematological) has been shown to be an independent prognostic factor for survival. 27 The interest in immunotherapy after hematopoietic stem cell transplantation has come from clinical observation of the GVT effect in the allogeneic context, [28][29][30] where the recognition of allo-major histocompatibility complex (MHC) leads to the killing of residual tumor cells as well as graft vs host disease. [31][32][33] In the autologous setting, patient survival is associated with a rapid recovery of lymphocytes, suggesting that the autologous immune system has the ability to fight residual tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Joao

Porrata

Inwards

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is an effective treatment strategy for mantle-cell lymphoma (MCL) demonstrating significantly prolonged progression-free survival (PFS) when compared to interferon-a maintenance therapy of patients in first remission. The study of absolute lymphocyte count at day 15 (ALC-15) after ASCT as a prognostic factor in non-Hodgkin lymphoma (NHL) included different lymphoma subtypes. The relationship of ALC-15 after ASCT in MCL has not been specifically addressed. We evaluated the impact of ALC-15 recovery on survival of MCL patients undergoing ASCT. We studied 42 consecutive MCL patients who underwent ASCT at the Mayo Clinic in Rochester from 1993 to 2005. ALC-15 threshold was set at 500 cells/ll. The median follow-up after ASCT was 25 months (range, 2-106 months). The median overall survival (OS) and PFS times were significantly better for the 24 patients who achieved an ALC-15 X500 cells/ll compared with 18 patients with ALC-15 o500 cells/ll (not reached vs 30 months, Po0.01 and not reached vs 16 months, Po0.0006, respectively). Multivariate analysis demonstrated ALC-15 to be an independent prognostic factor for OS and PFS. The ALC-15 X500 cells/ll is associated with a significantly improved clinical outcome following ASCT in MCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Joao

Porrata

Inwards

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…This was first demonstrated in experimental mice by Barnes and Loutit 5 and confirmed in humans with T-cell depleted HSCT experiments. This alloimmune state combined with the usual myeloablative regimens, especially total body irradiation, result in lasting growth disturbance, high risk of alloimmune disease, second cancers and early mortality, as described in the editorial and the reference cited above.…”

mentioning

confidence: 63%

“…3 However, the most relevant finding in two independent studies in PMF patients, was that a low JAK2 allele burden at diagnosis represented a strong surrogate marker associated with shortened survival. 4,5 Overall prognosis in PMF is poorer compared to other classic MPNs. An international prognostic score system (IPSS), which allows to discriminate four categories of patients with significantly different median survival, has been developed recently by…”

mentioning

confidence: 99%

Response to letter by Pulsipher et al.

Pinkel

2010

Leukemia

View full text Add to dashboard Cite

“…Bone marrow transplantation (Table 2) [9][10][11][12][13][14][15][16][17][18][19][20][21][22] had its roots in radiobiology and hematology, and it was influenced by clinical studies of certain inherited immune deficiency diseases. Early in these efforts it was learned that engraftment of histoincompatible bone marrow can cause lethal GVHD in a recipient rendered immunologically defenseless by cytoablation, a complication also predicted in recipients with immune deficiency disease.…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Historic Landmarks in Clinical Transplantation: Conclusions from the Consensus Conference at the University of California, Los Angeles

Groth

Brent²,

Calne

et al. 2000

World j. surg.

View full text Add to dashboard Cite

The transplantation of organs, cells, and tissues has burgeoned during the last quarter century, with the development of multiple new specialty fields. However, the basic principles that made this possible were established over a three-decade period, beginning during World War II and ending in 1974. At the historical consensus conference held at UCLA in March 1999, 11 early workers in the basic science or clinical practice of transplantation (or both) reached agreement on the most significant contributions of this era that ultimately made transplantation the robust clinical discipline it is today. These discoveries and achievements are summarized here in six tables and annotated with references.The symposium making up this issue of the Journal was held at the University of California, Los Angeles (UCLA) and announced by the Department of Surgery hosts as "a unique and historic meeting at which pioneers of transplantation from around the world will present and discuss landmarks in the advancement of transplantation biology." The participants (in alphabetical order) were: Leslie B. Brent (London), Roy Y. Calne (Cambridge, UK), Jean Dausset (Paris), Robert A. Good (St. Petersburg, FL), Joseph E. Murray (Boston), Norman E.Correspondence to: Carl G. Groth. NIH Public Access Author ManuscriptWorld J Surg. Author manuscript; available in PMC 2010 November 1. Published in final edited form as:World J Surg. 2000 July ; 24(7): 834-843. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptShumway (Palo Alto), Robert S. Schwartz (Boston), Thomas E. Starzl (Pittsburgh), Paul I. Terasaki (Los Angeles), E. Donnall Thomas (Seattle), Jon J. van Rood (Leiden).Each of these 11 pioneers provided for publication their reflections about their own unique contributions. The ultimate objective, however, was to reach a consensus by the group on what were the most critical historical discoveries that made transplantation a form of clinical therapy. Carl G. Groth (Stockholm) was invited to be the Chairman for these consensus deliberations and to prepare the executive summary.Historical landmark status was restricted to contributions made at least a quarter of a century ago. By this time it had been established that rejection of organ allografts could be prevented or reversed with immunosuppressive drugs and that variable donor-specific immunologic tolerance of the graft subsequently developed in many patients. Long-term survival of human recipients of organ and bone marrow allografts had been repeatedly obtained, ensuring continuation of such clinical efforts. A large number of HLA antigens had been discovered, allowing efforts at tissue matching to proceed. The scientific articles annotating this progress are listed in six tables under the following headings: transplantation immunology, bone marrow transplantation, renal transplantation, liver transplantation, heart transplantation, and tissue matching. The material presented in these tables, including the citations, originated from the participants of the symp...

show abstract

Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II

Cited by 222 publications

References 6 publications

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

Response to letter by Pulsipher et al.

Historic Landmarks in Clinical Transplantation: Conclusions from the Consensus Conference at the University of California, Los Angeles

Contact Info

Product

Resources

About